This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Explore when bonds may be preferred over the Sp500 in retirement and how a cautious mix can protect assets while supporting withdrawals. This intro covers key timing considerations and conservative principles.
23,766 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A seven-year high in regional bank M&A signals bigger players aiming for scale and efficiency. This guide breaks down...
Investors are weighing whether now is the time to buy SpaceX's stock after a pullback. This guide breaks down the dec...
Meta Platforms is nudging into cloud computing, aiming to monetize idle compute and AI-ready infrastructure. This art...
Tesla is quietly scaling its energy storage and grid modernization business, a growth engine many investors overlook ...
Ford faces renewed scrutiny as recalls mount and U.S. sales soften, fueling a debate over whether ford should give ba...
A midweek surge in Calumet stock followed news of debt reduction, shining a light on how balance-sheet improvements c...
A dramatic shift in SpaceX stock has traders buzzing. This article unpacks what spacex stock just made move means for...
Nike's latest sponsorship moves suggest a gradual return of brand influence and profit potential. This article explor...
Broadcom reports stronger AI chip demand through custom silicon, positioning the company to outpace Nvidia in the rem...
General Dynamics posted a strong first quarter, while Lockheed Martin unveiled a major Ultra Maritime purchase, sharp...
IBM recently released a preliminary quarter that underscored a broader pattern: AI budgets are shifting. This article...